EVENT BROCHURE

BioFormulate LIVE 2026

BioFormulate Live 2026

3–4 November 2026

London, UK

CO-LOCATED EVENTS

BIOLOGICS MANUFACTURING UK 2026

BIO OUTSOURCING EUROPE 2026

OFFICIAL EVENT BROCHURE

https://infohub.imapac.com/bioformulate-live-2026

Table of Contents

About the Event 3
Key Themes & Topics 4
Agenda at a Glance 4
Agenda 6
Meet the Speakers 15
Sponsors & Media Partner 19
Our Past Partners 20
Expected Audience Snapshot 23
Target Attendee Companies 24
Targeted Attendees List 26
Sponsorship Packages 28
Sponsorship Opportunities 29
Testimonials 30
Tickets 33
Venue 34
Travel Options 35
Accommodation Options 36
Floorplan 38
Add to Calendar 39
About IMAPAC 40

EVENT HIGHLIGHTS

200+ ATTENDEES

100+ COMPANIES

60+ EXPERT SPEAKERS

DATE & VENUE

3-4 November 2026

Radisson Blu Hotel, London Heathrow
140 Bath Road, Harlington, Hayes UB3 5AW, UK

CO-LOCATED EVENTS

BIOLOGICS MANUFACTURING UK 2026

BIO OUTSOURCING EUROPE 2026

About the Event

WHO / WHAT / WHY

WHO

For biopharma biotech and pharmaceutical leaders across Europe working in RNA design vaccine R&D biologics formulation drug delivery and stability science. This includes R&D Drug Product Analytical Development, CMC, Quality, Manufacturing professionals from leading pharmaceutical companies innovative biotechs, CDMOs, technology providers, and academic & research institutions.

WHAT

A strategic platform dedicated to advancing the next generation of biologics formulation, stability, and delivery. BioFormulate Live 2026 unites three concurrent scientific streams - RNA Therapeutics, Vaccine Innovation, and Biologics Formulation & Delivery, offering deep technical insights spanning early development through to commercial-scale production.

WHY

To accelerate innovation in biologics drug development by bringing together top scientific, technical, and regulatory experts. Attendees gain practical solutions to stability challenges, formulation optimisation, patient-focused delivery, and manufacturing scale-up. The event enables high-value collaboration, technology discovery, and future-focused insights at the junction where formulation science meets global healthcare impact.

WHAT TO EXPECT

200+
Senior Attendees

Meet a concentrated audience of biologics RNA and vaccine development leaders from global pharma biotechs CDMOs and academia.

60+
Expert Speakers

Hear from world class leaders in RNA engineering formulation science structural biology vaccine innovation and drug product development.

100+
Companies Represented

A pan European gathering representing biopharma technology providers regulatory bodies and academic institutions.

KEY THEMES & TOPICS

BioFormulate LIVE 2026

Novel Formulation Strategies for Complex Biologics
mAbs, Bispecifics, & ADCs

Adjuvants & Immunostimulatory Technologies
Amplifying Vaccine Potency

Formulation Supply Chain
From Clinical to Commercial

From Formulation to Device Integration

LNP & RNA Formulation

Smart Aseptic Fill–Finish

FEATURED TESTIMONIAL

"I had the pleasure of collaborating with the IMAPAC team during the Irish leg of the Biologics World event in February 2026. The organisers were exceptionally receptive and helpful, ensuring a seamless experience throughout the planning, exhibition logistics, partnering sessions, and sponsor visibility. Their proactive approach in connecting us with potential partners significantly enhanced our ROI. We are already exploring future opportunities to work with the IMAPAC team."

Terry Gray · Field Marketing Manager · Merck

Agenda at a Glance

DAY 1 | 3 NOVEMBER 2026
Novel Formulation Strategies for Complex Biologics - mAbs, Bispecifics, & ADCs
NETWORKING BREAK
Adjuvants & Immunostimulatory Technologies - Amplifying Vaccine Potency
LUNCH
Formulation Supply Chain – From Clinical to Commercial
Downstream Purification Optimisation
NETWORKING BREAK
Strategies For Selecting & Managing CDMOs
Industry Roundtables
END OF CONFERENCE DAY 1

Agenda at a Glance

DAY 2 | 4 NOVEMBER 2026
From Formulation to Device Integration
NETWORKING BREAK
Next-Generation Therapeutics: RNA, Formulation & Process Innovation
LUNCH
Smart Aseptic Fill–Finish
Supply Chain Resilience and Logistics
NETWORKING BREAK
Closing Panel Discussion: Future of European Biomanufacturing + Formulation
END OF CONFERENCE

BioFormulate 2026

Day 1

3 November 2026

08:00 **Registration & Coffee**

08:50

Chairman's Welcome Address

Darren Pitt
Chief Scientific Officer and Co-Founder, VisusNano, UK

Novel Formulation Strategies for Complex Biologics - mAbs, Bispecifics, & ADCs

09:00

Advanced Formulation Strategies for Complex Biologics: mAbs, Bispecifics & ADCs

- How dripping can impact filling process control
- Reported approaches to avoid dripping in a filling process
- Droplet elongation rate as an indicator of solution propensity for dripping
- Impact of surfactants on solution propensity for dripping at the nozzle tip end

Sébastien Dasnoy
Principal Scientist, Injectable Formulation Development, UCB, Belgium

09:25

Crack the Protein Formulation Code with Aunty

- Protein formulation labs face challenges every day: more samples to test, increasingly complex candidates, and shorter timelines.
- Optimizing stability, manufacturability, and developability requires extensive excipient screening across multiple parameters—all in less time than ever before.
- This talk shows how you can use Aunty to speed up formulation studies from weeks to days using high-throughput, multi-attribute characterization in a 96-well SBS-format quartz plate.
- By combining full-spectrum DSF, SLS, and DLS in a single experiment, you can gather all the melting and aggregation data necessary to make faster, more informed decisions while improving efficiency.
- Automation-ready workflows keep grinding out results long after you've called it a day.
- We'll review a DoE-based excipient screen of three antibodies and an enzyme that identified major stability drivers in a single experiment.
- We'll also peek into colloidal parameters kD* and B22*, as well as freeze/thaw performance to provide a more complete picture of formulation behavior.

Andre Mueller
Director, Product Manager, Unchained Labs, USA

Day 1

3 November 2026

09:50

From Bioprocess to Formulation: Building Robust and Scalable Strategies for Complex Biologics

Harsha Reddy
Group Lead - Head Upstream Process Development, CMC Bioprocess Lead, Accord BioPharma, UK

10:15

Cracking Long-Acting Injectables Translation: Lessons from Small Molecules, Implications for Biologics

- Early PK and biocompatibility data for small-molecule LAIs often fail to predict clinical outcomes, creating a persistent predictability gap.
- The injection site acts as a complex, dynamic system, where depot behavior, tissue response, and absorption are tightly linked.
- Traditional approaches (e.g., IVIVC) are insufficiently predictive, requiring a shift to mechanistic, model-informed translation.
- Success depends on integrated CMC–PK–clinical strategies that reduce uncertainty early through coordinated design.
- These learnings are relevant to high concentration /complex biologics, where greater molecular complexity further tightens the link between formulation, delivery, and clinical performance.

Marieta Duvnjak
Head Science & Operations in Analytical Research and Development, Novartis, India

10:40

Networking Break

Adjuvants & Immunostimulatory Technologies - Amplifying Vaccine Potency

11:10

The CMC Leader Driving Vaccines from Development to Real-World Supply

- Why scientific innovation alone is not enough to ensure successful vaccine or biologics commercialization
- Identifying future CMC challenges before they become development bottlenecks
- Designing products for manufacturability, affordability and sustainable global supply
- The role of strategic CMC leadership in driving vaccines from development to real-world supply

Christine Hägglund
VP CMC Development, Scandinavian Biopharma, Sweden

Day 1

3 November 2026

11:35

Workforce Value-at-Risk: Quantifying Talent Risk Across Biopharma Development and Manufacturing

Dr Jason Beckwith
SVP Talent Science & Thought Leadership, BioTalent, UK

12:00

Advancing Cancer Immunotherapies from Discovery to Clinical Development: Aligning Innovation, Formulation, and Patient Impact

- Avancing an active immunotherapy for melanoma (iSCIB1+) from early- to late-phase clinical development
- Aligning formulation, CMC, and manufacturing strategies to support clinical progression
- Leveraging translational insights to establish a robust potency assurance strategy
- Harnessing the advantages of DNA plasmid formulations to maximise patient outcomes

Callum Scott
Senior Vice President, Development, Scancell, UK

12:30

Lunch

Formulation Supply Chain – From Clinical to Commercial

13:30

Strengthening Cold Chain and Distribution Strategies for Complex Biologics and Advanced Therapies

- Ensuring end-to-end cold chain integrity for biologics and advanced therapies through robust temperature monitoring and control systems
- Mitigating distribution risks for temperature-sensitive products via real-time tracking, data visibility, and contingency planning
- Optimizing global logistics networks to support timely, compliant, and scalable delivery of complex therapies
- Strengthening collaboration across supply chain stakeholders to maintain product quality from manufacturing to patient delivery

Kellen LaVigne
Director, Supply Chain & Logistics, Aurion Biotech, USA

Day 1

3 November 2026

13:55

Implementing an Innovative Automated Tool to Speed Up Quality Assessments of Clinical and Commercial Drug Product Excursions Globally

- Managing Excursions to Protect Quality and Supply
- Automating Quality Impact Assessments
- Turning Stability Data into Decision Support
- Enabling Consistent Global Implementation
- Reducing Assessment Time by Approximately 50%

Paul de Goede
Principal Scientist Formulation Development, Johnson & Johnson Innovative Medicine, Netherlands

Downstream Purification Optimisation

14:20

Bispecific Purification: Double Trouble or Twice as Nice?

- Tackling complex product-related impurities in bispecific purification
- Impact of molecular design, clone selection and analytics on manufacturability
- Developing robust, scalable purification strategies for next-generation bispecifics
- Industrial case studies and key lessons learned

Gavin Wild
Head of Early Process Sciences, UCB, UK

Strategies for Selecting & Managing CDMOs

14:45

Partnering for Success: Integrating Internal Expertise with External Manufacturing Capabilities

- CDMO selection process, relationship management
- An example of what can be achieved when both parties are aligned on a shared vision.

Franz Schnetzinger
VP / Head PAD & QC, AAVantgarde Bio, UK

Day 1

3 November 2026

15:10

Managing CDMO Partnerships Across Formulation & Supply Networks (TBC)

- Selecting the right CDMO partners for formulation development, manufacturing, and commercial supply.
- Establishing governance models that drive performance, transparency, and long-term collaboration.
- Managing supply chain risks, capacity constraints, and business continuity across external networks.
- Using performance metrics and operational reviews to ensure quality, reliability, and on-time delivery.

Karen O'Hanlon
Chief Operating Officer, StablePharma, UK

15:35

Choosing the Right Outsourcing Partner: From Payload to Fill-Finish

- Evaluating CDMO capabilities across the full manufacturing workflow
- Strengthening collaboration and oversight across multi-partner supply chains

Abisola (Abi) Kuforiji
Associate Director-External Manufacturing -Operations lead (EMEA), MSD, Switzerland

16:00

ROUNDTABLE DISCUSSION

1. Formulation as a Commercial Differentiator
   Marco Carfagna — Head of Formulation Development & Drug Product Labs, Formycon, Germany
2. From Formulation to Patient: Designing Biologics for Access, Adoption, and Real-World Value
   Ahmed Abou Khatwa — Regional Patient Value and Access Director, Takeda, Singapore
3. From Formulation to Delivery: Designing Patient-Centric Therapeutic Platforms for Advanced Modalities
   Darren Pitt — Chief Scientific Officer and Co-Founder, VisusNano, UK

17:20 **Key Takeaways**

17:30 **Cocktail Reception**

18:00 **END OF CONFERENCE DAY 1**

BioFormulate 2026

Day 2

4 November 2026

08:00 **Registration & Coffee**

08:50

Chairman's Welcome Address

Darren Pitt
Chief Scientific Officer and Co-Founder, VisusNano, UK

From Formulation to Device Integration

09:00

Bridging Formulation, Manufacturing, and Process Development in Advanced Cell Therapies

- Integrating formulation, process development, and manufacturing to ensure consistent quality in advanced cell therapies
- Overcoming scale-up and variability challenges while maintaining cell viability and functional potency
- Developing closed, automated, and scalable processes to enable robust and reproducible cell therapy production
- Aligning cross-functional teams early to streamline tech transfer

Hollie Bartley
Director, Process Development, Resolution Therapeutics, UK

09:25

Nebulized IgG: A Combination Product Odyssey

- Phase appropriate solutions
- Innovation: Balancing development speed with program risk
- Combination product mind set: The whole is greater than the parts

Max Corbett
Senior Director, CMC Group Head Biologics and Small Molecule, CSL, Switzerland

09:50

Reserved for Solution Provider

Day 2

4 November 2026

10:15

Designing the System, Not the Parts: Early CMC and Device Integration in Combination Products

- Integrating CMC and device development early to ensure seamless compatibility between drug product and delivery system
- Designing combination products holistically to optimize performance, usability, and patient-centric administration
- Addressing manufacturability and assembly challenges through aligned drug–device development strategies
- Ensuring regulatory compliance by coordinating CMC, device, and combination product requirements from the outset

Ritupon Gogoi
Director, CMC (Biologics Fill-Finish and Drug-Device Combination Products), Zura Bio, UK

10:40 **Networking Break**

Next-Generation Therapeutics: RNA, Formulation & Process Innovation

11:10

The Controlled Temperature Chain and Lyophilised RNA Vaccines

- The motivation for producing lyophilised RNA vaccines
- Lipid nanoparticle formulations of mRNA and saRNA that are suitable for freeze-drying
- Parameters used to identify the formulation space and process analytical technology
- Physico-chemical characterisation and bioassay
- Early stability study read-outs.

Dr Christopher van der Walle
Head of Formulation Science, MHRA, UK

11:35

Turning Junk into Gems: Long Non-Coding RNAs Unlock New Therapeutic Horizons?

Alessandro Bonetti
Director, AstraZeneca, UK

12:00

New Strategies for Oral Delivery of Biologics

Dr Driton Vllasaliu
Reader in Biotherapeutics Delivery, King's College London, UK

12:25 **Lunch**

Day 2

4 November 2026

Smart Aseptic Fill–Finish

13:30

From Tech Transfer to Commercial Supply: Ensuring Quality in Fill–Finish Operations

Sarah Pasqualinotto
External Site Lead, External Operations (Associate Director), Biogen, Switzerland

13:55

From tech transfer to commercial supply, Digitalisation of the formulation, MSAT leadership in vaccines formulation fill and finish

Laurent Marcellin
Head of MSAT Vaccines, Takeda, Switzerland

14:15

Beyond OEE: Integrating Asset Excellence, Automation and Contamination Control in Pre-Filled Syringe Manufacturing

Tarik Cheema
Asset Excellence Lead Pre-Filled Syringes, Roche, Switzerland

Supply Chain Resilience & Logistics

14:40

CEPI: An Input Materials Supply Organization for African Vaccine Input Material A Supply Consortium Model: Scope, Governance and Investment

- Aggregating demand for critical vaccine input materials and consumables
- Defining the scope of an African supply consortium model
- Establishing governance structures and stakeholder responsibilities
- Exploring investment needs and long-term sustainability

Valerie Chambard-Benalleg
Manufacturing Supply Chain Lead, CEPI, UK

Day 2

4 November 2026

15:05

PANEL DISCUSSION

The Future of Biopharma Supply Chains – Building Resilience, Agility & Sustainability

MODERATOR

Dr Andreea Iftimia-Mander
Head of Analytical and Biological Sciences (SCS1), MHRA, UK

PANELLISTS

Brendan Noone
Senior Director, Global Supply Chain & Strategy, AstraZeneca, Ireland

Max Corbett
Senior Director, CMC Group Head Biologics and Small Molecule, CSL, Switzerland

Kristin Grande
Senior Manager, Technical Marketing - Life Sciences, Greenfield Global, USA

Shyam Panjwani
Senior Principal CMC Data Scientist, Bayer, USA

Kellen LaVigne
Director, Supply Chain & Logistics, Aurion Biotech, USA

15:45 — **Networking Break**

16:00

PANEL DISCUSSION

Future of European Biomanufacturing + Formulation

- Europe's biomanufacturing future depends on scaling advanced facilities while maintaining high regulatory and quality standards
- Strategic investment in automation, digitalisation and AI will be critical to offset high operating costs
- Strengthening local supply chains will improve resilience and reduce dependency on external geographies
- Bridging Formulation, Manufacturing, and Process Development for 2030

MODERATOR

Julia Hinteramskogler
Head of Technical Development, Elaris, Austria

PANELLISTS

Syed Saqib Naqvi
Senior Manager, Digital Excellence, Amicus Therapeutics, UK

Michael Palige
Process Development & CMC Lead, Takeda, Austria

Jose Martinez Calderon
QA R&D and Commercial Product Development Senior Director, Almirall, Spain

Darren Pitt
Chief Scientific Officer and Co-Founder, VisusNano, UK

16:45 — **Closing Remarks**

17:00 — **END OF CONFERENCE**

MEET THE SPEAKERS

BioFormulate LIVE 2026



Ahmed Abou Khatwa

Regional Patient Value and Access Director
Takeda
SINGAPORE



Dr Christopher van der Walle

Head of Formulation Science
MHRA
UK



Paul de Goede

Principal Scientist Formulation Development
Johnson & Johnson Innovative Medicine
NETHERLANDS



Tarik Cheema

Asset Excellence Lead Pre-Filled Syringes
Roche
SWITZERLAND



Marieta Duvnjak

Head Science & Operations in Analytical Research and Development
Novartis
INDIA



Max Corbett

Senior Director, CMC Group Head Biologics and Small Molecule
CSL
SWITZERLAND



Sarah Pasqualinotto

External Site Lead, External Operations (Associate Director)
Biogen
SWITZERLAND



Laurent Marcellin

Head of MSAT Vaccines
Takeda
SWITZERLAND



Alessandro Bonetti

Director
AstraZeneca
UK



Brendan Noone

Senior Director, Global Supply Chain & Strategy
AstraZeneca
IRELAND



Sébastien Dasnoy

Principal Scientist, Injectable Formulation Development
UCB
BELGIUM



Hollie Bartley

Director, Process Development
Resolution Therapeutics
UK

BioFormulate LIVE 2026



Kellen LaVigne
Director, Supply Chain & Logistics
Aurion Biotech
USA



Christine Hägglund
VP CMC Development
Scandinavian Biopharma
SWEDEN



Ritupon Gogoi
Director, CMC (Biologics Fill-Finish and Drug-Device Combination Products)
Zura Bio
UK



Marco Carfagna
Head of Formulation Development & Drug Product Labs
Formycon
GERMANY



CHAIRMAN

Darren Pitt
Chief Scientific officer and Co-founder
VisusNano
UK



Harsha Reddy
Group Lead - Head Upstream Process Development, CMC Bioprocess Lead
Accord BioPharma
UK



Dr Driton Vllasaliu
Reader in Biotherapeutics Delivery
King's College London
UK



Callum Scott
Senior Vice President, Development
Scancell
UK



Andre Mueller
Director, Product Manager
Unchained Labs
USA

BIOLOGICS MANUFACTURING UK 2026



CHAIRMAN

Dr Uwe Gottschalk
Operating Partner
Keensight Capital
FRANCE



Dr Andreea Iftimia-Mander
Head of Analytical and Biological Sciences (SCS1)
MHRA
UK



Niveth Richard
Supply Chain Decision Intelligence Lead
GSK
UK



Marcelo Castro
Senior Director, Global Biopharma External Supply Operations Quality
Pfizer
IRELAND



Shyam Panjwani
Senior Principal CMC Data Scientist
Bayer
USA



Dirk Boehm
Site Head DS Penzberg (VP)
Roche
GERMANY



Ian Baldacchino
Vice President, Global Head of Internal Manufacturing Quality
UCB
BELGIUM



Mathias Van den Borre
Head of Digital Innovation, Global Quality
UCB
BELGIUM



Gavin Wild
Head of Early Process Sciences
UCB
UK



Dr John Bridgeman
Chief Scientific Officer
ImmunoKey
UK



Alexander Hempel
Director Manufacturing
Avethera
GERMANY



Dr Aurelien Bunga
Senior Scientist
Rinri Therapeutics
UK



Vishal Mukund Sonje
Senior Vaccine Manufacturing Lead
CEPI
UK



Dr Warren Roche
Senior Biostatistician Expert
Argenx
BELGIUM





Michael Palige
Process Development & CMC Lead
Takeda
AUSTRIA



Syed Saqib Naqvi
Senior Manager, Digital Excellence
Amicus Therapeutics
UK



Kristin Grande
Senior Manager, Technical Marketing - Life Sciences
Greenfield Global
USA

BIO OUTSOURCING EUROPE 2026



Filippo Ramondelli
Associate Director - TT & Project Management Lead
Takeda
ITALY



Tejash Shah
Senior Director, Biopharm CMC Regulatory Affairs
GSK
UK



Cathal Gallagher
Senior Director-Head of Quality, External Operations EU
Takeda
IRELAND



Abisola (Abi) Kuforiji
Associate Director-External Manufacturing -Operations lead (EMEA)
MSD
SWITZERLAND



Jose Martinez Calderon
QA R&D and Commercial Product Development Senior Director
Almirall
SPAIN



Anthony Beaney
Principal Scientist
Lonza Biologics
UK



Valerie Chambard-Benalleg
Manufacturing Supply Chain Lead
CEPI
UK



Julia Hinteramskogler
Head of Technical Development
Elaris
AUSTRIA



Franz Schnetzinger
VP / Head PAD & QC
AAVantgarde Bio
UK



Karen O'Hanlon
Chief Operating Officer
StablePharma
UK



Dr Ashwinkumar V Meru
Head of Global Business Development
Kemwell
INDIA



Giorgio Salciarini
Head of Sales - Technical Business Development
BSP Pharmaceuticals
ITALY

Sponsors & Media Partner

GOLD

BSP PHARMACEUTICALS

BRONZE

KEMWELL
KEEPING YOU COMPETITIVE

UNCHAINED LABS

INPROCESS LSP
Innovators in Process Analytical Technology

EXHIBITION & NETWORKING

QuickSTAT
A Kuehne+Nagel Company

BRIGGS

ASSOCIATE

MabPlex

GREENFIELD GLOBAL

ALFA LAVAL

ASTec Chemicals


Our Past Partners



Our Past Partners (cont.)



Our Past Partners (cont.)



Expected Audience Snapshot

45%
BIOPHARMA & BIOTECH

30%
BIG PHARMA

15%
TECHNOLOGY PROVIDERS CDMOS AND CROS

10%
ACADEMIC AND RESEARCH INSTITUTIONS

BY PROFILE

Formulation, Delivery & Stability	32%
R&D: Drug Product, RNA / Next-Generation Modalities	22%
Analytical Development & Characterisation	18%
CMC & Regulatory Affairs	10%
Supply Chain / Planning	10%
Manufacturing, Process Development & Scale-Up	18%


BY JOB TITLE

Directors & VPs of Formulation, Drug Product, R&D	28%
Heads of RNA Development	18%
Heads of Vaccine R&D	16%
Principal Scientists (Formulation & Biophysics)	22%
CMC Strategy Leaders	10%
Device & Drug Delivery Engineers	6%

DECISION MAKERS

Directors, Heads, Senior Managers	60%
C-level, VPs, and Global Leads	25%
Scientists, Researchers, and Technical Specialists	15%

BY GEOGRAPHY



Target Attendee Companies

BIG PHARMA

26 companies

AstraZeneca, Otsuka, Biogen, Bristol Myers Squibb, Pfizer, moderna, Takeda, abbvie, Daiichi-Sankyo, sanofi, Lilly, Lundbeck, Bayer, GSK, Novartis, novo nordisk, Johnson & Johnson, CSL Behring, Boehringer Ingelheim, MSD, AMGEN, astellas, Gilead, Santen, Roche, IPSEN

BIOPHARMA

59 companies

CellCentric, CureVac, Exscientia, evox, formycon, morphosys, IKSUDA THERAPEUTICS, LEGEND BIOTECH, VERTEX, beacon therapeutics, CSL Seqirus, gritstone, ingenza, AMPHISTA THERAPEUTICS, Complement Therapeutics, CYCLE PHARMA, AVIADOBIO, Bicycle, Callidus, DARK BLUE THERAPEUTICS, OXFORD BioTherapeutics, QuellTx, sitryx, argenx, astronauTx

Target Attendee Companies (cont.)

BIOPHARMA continued

59 companies

Autolus, MyricxBio, IMMUNOCORE, PHOREMOST, REVOLO BIOTHERAPEUTICS
ucb, ACHILLES THERAPEUTICS, Adaptimmune, ANTIKOR INNOVATION IN ADCs, BARINTHUS BIOTHERAPEUTICS
Relation, SCANDINAVIAN BIOPHARMA, SiftrBio, almirall, Alnylam
BIONTECH, Crescendo biologics, FREELINE, GRIFOLS, Oxford Biomedica
PHEON THERAPEUTICS, INmuneBio INNATE IMMUNITY, SPIREA, valneva, Amicus Therapeutics
APOLLO THERAPEUTICS, Benevolent AI, mission therapeutics, SHIONOGI, BiVictriX THERAPEUTICS
MOGRIFY, IMMUNOKEY, MEIRAGTx, Rinri Therapeutics

CDMOS

19 companies

Lonza, SAMSUNG BIOLOGICS, KEMWELL, AGC Biologics, Catalent Pharma Services
serán, ALMAC, curia, VETTER, WuXi Biologics
pci PHARMA SERVICES, MabPlex, MilliporeSigma, BIO-PHARMA SERVICES, BSP PHARMACEUTICALS
FUJIFILM, proveo, CARBOGEN AMCIS, Recipharm Advanced Bio

Targeted Attendees List

Companies and senior roles represented across the selected event(s)

JOB TITLE	COMPANY	COUNTRY
Head of Manufacturing Science & Technology	AbbVie	UK
Head of Biologics Facility	AbbVie	UK
Head of Tech Transfer	AbbVie	UK
Head of Manufacturing Science & Technology	AbbVie	UK
Head of Biologics Facility	AbbVie	UK
Head of Tech Transfer	AbbVie	UK
Director MSAT Formulation	AbbVie	UK
Vice President Technical Operations	Achilles Therapeutics Limited	UK
Director MSAT Cell & Gene Therapy	Adaptimmune	UK
Director MSAT Cell & Gene Therapy	Adaptimmune	UK
Director MSAT CGT	Adaptimmune	UK
Senior Director MSAT CGT	Adaptimmune	UK
Head of Cell Therapy Manufacturing	Adaptimmune	UK
Head of Cell Therapy Site	Adaptimmune	UK
Head of CGT Process Development	Adaptimmune	UK
Head of Cell Therapy Manufacturing	Adaptimmune	UK
Head of Cell Therapy Site	Adaptimmune	UK
Head of MSAT CGT	Adaptimmune	UK
Head of CGT Process Development	Adaptimmune	UK
Associate Director, Clinical Operations	Adaptimmune	UK
Analytical And Process Development Scientist	Adaptimmune	UK

Targeted Attendees List (cont.)

JOB TITLE	COMPANY	COUNTRY
Director, Manufacturing Science & Technology	Almac	UK
Associate Director, Clinical Operations	Alnylam Pharmaceuticals	UK
Vice President, Business Operations International	Alnylam Pharmaceuticals	UK
Senior Director, Clinical Operations	Alnylam Pharmaceuticals	UK
Director Clinical Operations	Alnylam Pharmaceuticals	UK
Associate Director, TMF Operations	Alnylam Pharmaceuticals	UK
Manager, Clinical Operations	Alnylam Pharmaceuticals	UK
Director, Research & Early Development Operations	Alnylam Pharmaceuticals	UK
Director Tech Ops Biologics	Amgen	UK
Director Site Operations	Amgen	UK
Director Process Transfer	Amgen	UK
Director Tech Ops Biologics	Amgen	UK
Director Site Operations	Amgen	UK
Director Process Transfer	Amgen	UK
Director Technical Operations Biologics	Amgen	UK
Director MSAT Fill-Finish	AstraZeneca	UK
Director MSAT ADC Development	AstraZeneca	UK
Director MSAT Fill-Finish	AstraZeneca	UK
Director MSAT Process Engineering	AstraZeneca	UK

VIEW THE FULL ATTENDEE LIST →

Sponsorship Opportunities

Sponsorship Packages

DIAMOND

PACKAGE INCLUDES

- Full-day workshop for 30 pax: room, lunch, 2 refreshment breaks, coffee / tea
- Keynote solo presentation: 20 min + 5 min Q&A
- 25-minute end-user client case study
- 12 sqm exhibition space (4×3m booth + banner)
- 1 speaker pass; 7 guest passes; 2 exhibitor passes
- 10 onsite 1:1 meetings
- Lead retrieval

PLATINUM

PACKAGE INCLUDES

- Half-day workshop for 30 pax: room, 1 refreshment break, coffee / tea
- Prime-billing solo presentation: 20 min + 5 min Q&A
- 25-minute end-user client case study
- 12 sqm exhibition space (4×3m booth + banner)
- 1 speaker pass; 7 guest passes; 2 exhibitor passes
- 10 onsite 1:1 meetings
- Lead retrieval

GOLD

PACKAGE INCLUDES

- Prime-billing solo presentation: 20 min + 5 min Q&A
- 9 sqm exhibition space (3×3m booth + banner)
- 1 speaker pass; 5 guest passes; 2 exhibitor passes
- 10 onsite 1:1 meetings
- Lead retrieval

SILVER (ENHANCED)

PACKAGE INCLUDES

- Solo presentation: 20 min + 5 min Q&A
- 6 sqm exhibition space (3×2m booth + banner)
- 1 speaker pass; 3 guest passes; 2 exhibitor passes
- 5 onsite 1:1 meetings
- Lead retrieval

SILVER

PACKAGE INCLUDES

- Solo presentation: 10 min + 5 min Q&A
- 6 sqm exhibition space (3×2m booth + tabletop display)
- 1 speaker pass; 2 guest passes; 2 exhibitor passes
- 5 onsite 1:1 meetings
- Lead retrieval

BRONZE

PACKAGE INCLUDES

- Solo presentation: 10 min + 5 min Q&A
- 6 sqm exhibition space (3×2m booth)
- 1 speaker pass; 2 guest passes
- Lead retrieval

EXHIBITION + 10 MEETINGS

PACKAGE INCLUDES

- 6 sqm exhibition space (3×2m booth + banner)
- 1 guest pass; 2 exhibition passes
- 10 onsite 1:1 meetings
- Lead retrieval

EXHIBITION + 5 MEETINGS

PACKAGE INCLUDES

- 6 sqm exhibition space (3×2m booth + banner)
- 1 guest pass; 2 exhibition passes
- 5 onsite 1:1 meetings
- Lead retrieval

EXHIBITION

PACKAGE INCLUDES

- 6 sqm exhibition space (3×2m booth + banner)
- 1 guest pass; 2 exhibition passes
- Lead retrieval

Sponsorship Opportunities

BioFormulate 2026

Who Should Sponsor?

- RNA Technology and Delivery Platform Providers
- LNP and Non Viral Delivery Developers
- Bioprocessing Equipment Manufacturers
- CDMOs CMOs RNA vaccines biologics
- Analytical and Characterisation Tool Providers
- Drug Delivery Device Engineering Firms
- Excipients and Raw Material Suppliers
- Cold Chain Packaging and Fill Finish Solution Providers
- Software Automation and AI Providers for Drug Product and Stability

Why Sponsor

SPONSORSHIP BENEFITS

- Thought Leadership Speaking
- Panel Participation
- Solution Showcases
- Engagement and Visibility Opportunities
- Branding and Digital Visibility
- Exclusive Networking

TESTIMONIALS

The Biologics and CGT Manufacturing DACH conference 2026 was very well planned and coordinated. It provided high-quality talks for staying up-to-date in our industry and I specifically enjoyed the time for networking.



Dr Heiner Apeler
VP Head of Biologics Development
Bayer
GERMANY

Thanks for the invite to speak at the event. It was a really enjoyable meeting and a great opportunity to present our work to the community. Identifying key partners for ImmunoKey's development plan is a critical aspect of getting our therapies to patients; the CGT and Biologics Manufacturing DACH meeting offered us the opportunity to engage with key CDMOs who can help us achieve this goal.



John Bridgeman
CSO
Immunokey
UK

Just back from an incredible time at the Biologics Manufacturing DACH congress! I have to be honest - as someone in Procurement, some of the deep-dives into Cell & Gene and biologics development were definitely above my scientific capabilities! However, the exchange of knowledge was fantastic, and it was a privilege to learn from such brilliant minds. A true highlight was the fantastic collaboration with Christopher Pawlak (PhD) . I had the privilege of co-hosting a round table with him focused on the impact of tariffs in the biopharma world. Christoph, thank you for the partnership - it was a truly dynamic discussion! 🤝 One of my biggest takeaways is that we have officially entered the era of "The Great Reshoring". We are moving past the days when drug manufacturing decisions were purely scientific; they are now deeply geopolitical. As we discussed in our round table, we can no longer just react to change. We have to treat scenario planning like a muscle that we train constantly to design for volatility. The event really hit home how much our world is changing - from the incredible progress in biologics manufacturing to the AI evolution. I'm excited to see how we can implement these insights to build resilience and benefit BMS biologics manufacturing. Back to my desk, I will start with socializing the learnings with my colleagues. A huge thank you to Drishti G. for the flawless organization and to Noel Murphy for approving the trip and supporting this critical learning opportunity!



Dennis Stelljes
Associate Director, Strategic Sourcing & Procurement, Biologics External Manufacturing
BMS
SWITZERLAND

TESTIMONIALS (cont.)

Really well organised conference with great attendees and high engagement - I was delighted to have taken the time to attend and really enjoyed sharing my thoughts on Accelerating Biologics Pipeline and ensuing discussion. Thank you to all organisers and facilitators



Dr Andrew Kelly
Director, Manufacturing Technology
BMS
IRELAND

A fantastic deep dive into the DACH region's CGT landscape. This conference made one thing clear: efficacy is proven, but industrialization is the new frontier. To truly move the needle, we must look beyond the lab and focus on scaling automation, streamlining supply chains, and tackling COGS. The diversity of voices - from large corporations, to tech suppliers and academic pioneers - provided a 360-degree view of the manufacturing challenges we must solve together.



Dr Thomas Villiger
Professor of Bioprocess Technology
University of Applied Sciences and Arts Northwestern Switzerland FHNW
SWITZERLAND

Thanks for the invite. The conference was really excellent, due to the caliber and engagement of the attendees.



Brian O'Connor
VP Global Quality
Orchard Therapeutics
UK

Thanks for putting this together! I enjoyed the discussions, atmosphere and engagement of participants. Great to be there!



Alvaro Avivar-Valderas
Associate Director - Cell Therapy Technology & Product Engine
Takeda
SPAIN

TESTIMONIALS (cont.)

I thoroughly enjoyed attending the CGT Manufacturing DACH 2026 by IMAPAC. The program featured exceptionally industry-relevant talks that provided deep insights into the current landscape. Beyond the sessions, the networking opportunities were top-tier, thanks to the high caliber of participants.



Steffen Schulze
Strategic Analytics & Business Analytics Lead
Roche
SWITZERLAND

I had the pleasure of collaborating with the IMAPAC team during the Irish leg of the Biologics World event in February 2026. The organisers were exceptionally receptive and helpful, ensuring a seamless experience throughout the planning, exhibition logistics, partnering sessions, and sponsor visibility. Their proactive approach in connecting us with potential partners significantly enhanced our ROI. We are already exploring future opportunities to work with the IMAPAC team.

Terry Gray
Field Marketing Manager
Merck

Thank you for your email and organising this wonderful event. It was a pleasure to participate. Congratulations on organising this event. It was a wonderful opportunity to present our work and to collaborate with others in the area. Looking forward to your next event



Warren Roche
Senior Statistical Expert
Sanofi
IRELAND

Thank you, it was a pleasure meeting you, and your enthusiasm made it an engaging and positive event. I hope we have opportunity to connect again in the future.



Michael Inglis
Head of Manufacturing Sciences, Analytical Technologies
Chiesi Farmaceutici Global Rare Disease
IRELAND

Well done on a very informative and successful event.



Shada Warreth
Global Partnerships Implementation Senior Manager
NIBRT
IRELAND

TICKETS



BP

FROM

£699

+ VAT

Book now



SSP

FROM

£2895

+ VAT

Book now

Book online at **infohub.imapac.com/bioformulate-live-2026**

VENUE



Radisson Blu Hotel, London Heathrow

ADDRESS

140 Bath Road, Harlington, Hayes UB3 5AW, UK

OPEN MAP →

DATES & LOCATION

3-4 November 2026 | Radisson Blu Hotel, London Heathrow, London, United Kingdom

Travel Options

We look forward to welcoming you to our event at the Radisson Blu Hotel, conveniently located just minutes from Heathrow Airport. Please find travel guidance below to help you plan your journey.

By London Underground

45–60 MINUTES

Take the London Underground Piccadilly Line toward Heathrow Airport.

Estimated travel time: 45–60 minutes from central London.

- Alight at Heathrow Terminal 2 & 3 Underground Station
- From the station, the hotel is a short taxi or bus journey away

From Heathrow Airport

10–20 MINUTES

The hotel is located along Bath Road, with regular bus services connecting all terminals.

Estimated travel time: 10–20 minutes

- Local bus routes: 105, 111, 140, 285
- Hotel Hoppa shuttle service also available
- Alight on Bath Road, a short walk from the hotel

Taxi or Ride-Hailing

5–10 MINUTES

Taxis and ride-hailing services are readily available at all Heathrow terminals.

Estimated travel time: 5–10 minutes Estimated cost: £10–£20

By Car

The hotel is easily accessible by road:

- Address: 140 Bath Road, Hayes, Middlesex, UB3 5AW
- Located just off the M4 motorway

From Other UK Cities

For guests travelling from outside London:

- Arrive at London Paddington Station
- Continue via: Heathrow Express (fastest option), or Elizabeth line (cost-effective alternative)
- Transfer to bus or taxi for the final leg

Accommodation Options

Explore recommended hotels near the venue.

EXCLUSIVE DELEGATE HOTEL RATE

Please note:the conference registration fee does not include hotel accommodation or travel expenses.

IMAPAC has secured an exclusive discounted room rate for conference delegates. Use one of the booking options below and quote the conference block code where applicable.

Please complete your booking by03 October 2026to secure the discounted conference rate. Bookings made after the cut-off date are subject to hotel availability and may be charged at the prevailing room rate.

Standard Double Room

Single occupancy	£129.00
Double occupancy	£139.00

Rates include full breakfast.

Call the Radisson Blu Hotel, London Heathrow at**+44 (0)20 8759 6311**and quote the block code**"BIOF021126".**

Option 2 – By Email

Email the Radisson Blu Hotel, London Heathrow Reservations Team at**reservations.heathrow@radissonblu.com** and quote the block code**"BIOF021126".**

Email Hotel

Accommodation Options

Explore recommended hotels near the venue.



Radisson Blu Hotel, London Heathrow

VENUE FOR THIS EVENT

140 Bath Road, Hayes, Middlesex, UB3 5AW

BOOK A ROOM →



London Heathrow Mariott Hotel

4 MINUTE WALK FROM VENUE

Bath Road Heathrow, Airport, Hayes UB3 5AN

BOOK A ROOM →

accom 3

Ibis Style London Heathrow Airport

8 MINUTE WALK FROM VENUE

272 Bath Rd, London UB3 5AY

BOOK A ROOM →



Premier Inn London Heathrow


5 MINUTE DRIVE FROM VENUE

15 Bath Rd, London TW6 2AB

BOOK A ROOM →

Floorplan

Please find the booth allocation in the table below.



BOOTH ALLOCATION

3	Briggs of Burton
4	Alfa Laval
7a	MabPlex
7b	Greenfield Global
8	BSP Pharmaceuticals
11	QuickSTAT
14	AsTec Chemicals
17	Unchained Labs
18	Kemwell Biopharma
19	Inprocess LSP

VIRTUAL TOURS

Virtual Tour of Commonwealth Suite


OPEN VIRTUAL TOUR →

Virtual Tour of the Atrium

OPEN VIRTUAL TOUR →

Virtual Tour of Royal Suite

OPEN VIRTUAL TOUR →



Event venue floorplan

MARK YOUR CALENDAR

Save the Date

3–4 NOV 2026

Radisson Blu Hotel

BioFormulate Live 2026

ALL IMAPAC EVENTS

Explore Our Full Event Calendar

Discover upcoming IMAPAC biopharmaceutical conferences, summits, and exhibitions across Europe and worldwide.

→

OR ADD THIS EVENT TO YOUR CALENDAR

Google Calendar
One-click add to Gmail →

Outlook Calendar
Add to Microsoft Outlook →

Scan to Register

Open camera, point at code, instant registration access.

Or click the QR to open registration directly.

A VARIETY OF PRODUCTS TO CATER TO GLOBAL BIOPHARMACEUTICAL INDUSTRY'S MARKET INTELLIGENCE AND BUSINESS CONNECTIONS NEEDS.

01 B2B EVENTS

Thought-leadership, industry knowledge-sharing and quality networking are at the core of IMAPAC's B2B events.

Create an engaging experience for your audiences, explore our B2B Events Solutions.

02 360 MARKETING SOLUTIONS

Expand your reach and influence! Be it with customized events, digital marketing solutions, content creation or thought-leadership.

Tap into our global audience spanning the sub-sectors and regions shaping the biopharmaceutical industry.

03 DASHBOARDS

A quick-view analytics tool to power your decisions. Access region or country-specific data to uncover pipeline information, product focus.

Customize the dashboard based on your needs. Drill down to the data you need using custom views.

04 CUSTOM RESEARCH

Based on your objectives and budget, you can customize a package to one that best meets your intelligence needs. This allows you to maximize your ROI without spending on items that are not in line with your strategies.

With access to a database of 60,000+ life science professionals. We conduct research with a highly-qualified audience.

05 REPORTS

Discover in-depth market information of the growing biopharmaceutical sector.

Learn More →

HELPING THE GLOBAL BIOPHARMACEUTICAL INDUSTRY

Generate Tangible Growth

IMAPAC is the one-stop shop of market intelligence and business connections for the global biopharmaceutical industry. We help companies expand their influence, make data driven decisions through our industry intelligence, and link up with other biopharmaceutical professionals to exchange knowledge and engage in quality networking. At the core of IMAPAC is our mission to help biopharmaceutical businesses globally generate tangible growth. At the same time, our heart lies in giving back to society. We empower the next generation by equipping underprivileged children with an education.

WEBSITE
imapac.com

EMAIL
info@imapac.com

IMAPAC PTE LTD
36 Robinson Road, #02-01
Singapore 068877
+65 6983 6140

IMAPAC UK LTD
77 Farringdon Road, Farringdon
London EC1M 3JU, United Kingdom
+44 161 552 8507

CONNECT WITH US

LINKEDIN
@imapac

X
@imapac

FACEBOOK
ImapacPteLtd